Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2010

01-10-2010 | Clinical Research

Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients

Authors: Leyla Nazal, Arnoldo Riquelme, Nancy Solís, Margarita Pizarro, Alex Escalona, Mauricio Burotto, Juan Ignacio Méndez, Catalina Saint-Jean, María José Concha, Stefano Giovanni, Diego Awruch, Arturo Morales, Rene Baudrand, Gonzalo Carrasco, María Angélica Domínguez, Oslando Padilla, Manuel Espinoza, Juan Francisco Miquel, Flavio Nervi, Marco Arrese

Published in: Obesity Surgery | Issue 10/2010

Login to get access

Abstract

Background

Reduced serum levels of adiponectin have been associated with insulin resistance and non-alcoholic fatty liver disease (NAFLD). However, the relationship between serum adiponectin levels and hepatic histology in NAFLD is controversial. The aim of this study was to explore associations between plasma adiponectin concentrations and liver histology in morbidly obese patients.

Methods

We conducted a case–control study including obese patients undergoing bariatric surgery and normal controls. Anthropometric, standard biochemical variables as well as plasma adiponectin and leptin levels were determined. Liver biopsy was performed in all patients at the time of surgery.

Results

Seventy morbidly obese patients (mean BMI, 40.6 ± 5.6 kg/m2) met the inclusion criteria and were compared with 69 controls (mean BMI, 22.8 ± 1.6 kg/m2, p = 0.0001). Thirty patients (43%) had NAFLD and 20 (28%) of them fulfilled the histological criteria for steatohepatitis. Obesity was associated with increased leptin and decreased adiponectin levels. NAFLD patients exhibited decreased levels of serum adiponectin compared with matched controls [median (Q1–Q3), 3.9 (3.2–4.3) vs. 8.6 (6.5–9.2) μg/mL, p < 0.0001]. In univariate analysis, age, gender, type 2 diabetes mellitus, BMI, HOMA-IR, aspartate aminotransferase (AST), alanine aminotransferase, serum glucose, and adiponectin levels were independently associated with hepatic fibrosis. In multivariate analysis, AST [OR = 1.082 (1.000–1.170)], age [OR = 1.119 (1.023–1.225)], and serum adiponectin levels [OR = 0.529 (0.299–0.936)] were significantly associated with the presence of liver fibrosis.

Conclusions

NAFLD patients have lower plasma adiponectin concentrations than control subjects. Low adiponectin levels are associated with more severe liver histology. Serum adiponectin may be useful to estimate the severity of liver damage in obese patients with NAFLD.
Literature
1.
2.
Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9.CrossRefPubMed
3.
Riquelme A, Arrese M, Soza A, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29:82–8.CrossRefPubMed
4.
5.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed
6.
Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–9.CrossRefPubMed
7.
Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176–84.CrossRefPubMed
8.
de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104–12.PubMed
9.
Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.CrossRefPubMed
10.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.CrossRefPubMed
11.
Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11:1–16. vii.CrossRefPubMed
12.
Marra F, Gastaldelli A, Svegliati Baroni G. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72–81.CrossRefPubMed
13.
Arrese M. Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology. 2009;49:348–51.CrossRefPubMed
14.
Perlemuter G, Bigorgne A, Cassard-Doulcier AM, et al. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab. 2007;3:458–69.CrossRefPubMed
15.
Arner P. Insulin resistance in type 2 diabetes—role of the adipokines. Curr Mol Med. 2005;5:333–9.CrossRefPubMed
16.
Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine–adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131:934–45.CrossRefPubMed
17.
Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036–42.CrossRefPubMed
18.
Guerre-Millo M. Adiponectin: an update. Diabetes Metab. 2008;34:12–8.PubMed
19.
Wang J, Brymora J, George J. Roles of adipokines in liver injury and fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:47–57.CrossRefPubMed
20.
Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.CrossRefPubMed
21.
Lopez-Bermejo A, Botas P, Funahashi T, et al. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf). 2004;60:256–63.CrossRef
22.
Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117–21.CrossRefPubMed
23.
Kowdley KV, Pratt DS. Adiponectin—tipping the scales from NAFLD to NASH? Gastroenterology. 2005;128:511–3 (author reply 513).CrossRefPubMed
24.
Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29:1431–8.CrossRefPubMed
25.
Arrese M, Riquelme A. The value of serum adipokine measurement in non-alcoholic fatty liver disease. Liver Int. 2009;29(9):1291–3.CrossRefPubMed
26.
Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498–504.CrossRefPubMed
27.
Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–6.CrossRefPubMed
28.
Boza C, Riquelme A, Ibanez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–53.CrossRefPubMed
29.
Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.CrossRefPubMed
30.
Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology. 1998;115:937–46.CrossRefPubMed
31.
Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis. 2004;8:501–19. vii.CrossRefPubMed
32.
Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:37–54. viii.CrossRefPubMed
33.
Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102:2716–7.CrossRefPubMed
34.
Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63.CrossRefPubMed
35.
Acosta AM, Escalona M, Maiz A, et al. Determination of the insulin resistance index by the homeostasis model assessment in a population of Metropolitan Region in Chile. Rev Med Chil. 2002;130:1227–31.PubMed
36.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMed
37.
Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71–9.CrossRefPubMed
38.
American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30 Suppl 1:S4–41.CrossRef
39.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRef
40.
Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992;55:615S–9S
41.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed
42.
Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100.PubMed
43.
Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21.CrossRefPubMed
44.
Vuppalanchi R, Marri S, Kolwankar D, et al. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol. 2005;39:237–42.CrossRefPubMed
45.
Savvidou S, Hytiroglou P, Orfanou-Koumerkeridou H. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol. 2009;43:765–72.CrossRefPubMed
46.
Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18:1430–7.CrossRefPubMed
47.
Munoz LE, Cordero P, Torres L, et al. Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis. Ann Hepatol. 2009;8:123–8.PubMed
48.
Targher G, Bertolini L, Rodella S, et al. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2006;64:337–41.CrossRef
49.
Carroll JF, Chiapa AL, Rodriquez M, et al. Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity (Silver Spring). 2008;16:600–7.CrossRef
50.
Richardson DK, Schneider J, Fourcaudot MJ, et al. Association between variants in the genes for adiponectin and its receptors with insulin resistance syndrome (IRS)-related phenotypes in Mexican Americans. Diabetologia. 2006;49:2317–28.CrossRefPubMed
Metadata
Title
Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients
Authors
Leyla Nazal
Arnoldo Riquelme
Nancy Solís
Margarita Pizarro
Alex Escalona
Mauricio Burotto
Juan Ignacio Méndez
Catalina Saint-Jean
María José Concha
Stefano Giovanni
Diego Awruch
Arturo Morales
Rene Baudrand
Gonzalo Carrasco
María Angélica Domínguez
Oslando Padilla
Manuel Espinoza
Juan Francisco Miquel
Flavio Nervi
Marco Arrese
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 10/2010
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-009-0051-0

Other articles of this Issue 10/2010

Obesity Surgery 10/2010 Go to the issue

Clinical Report

Laparoscopic Gastric Band Migration: Role of Environmental Factors in the Experience of a Single Team in Three Operating Rooms

Clinical Research

A Novel Surgical Technique: Single-Incision Transumbilical Laparoscopic Roux-en-Y Gastric Bypass

Clinical Research

Do Gastric Bypass Patient Characteristics, Behavior, and Health Differ Depending upon how Successful Weight Loss is Defined?

Clinical Research

Small Bowel Obstruction After Antecolic and Antegastric Laparoscopic Roux-en-Y Gastric Bypass: Could the Incidence be Reduced?

Case Report

An Evaluation of the Rapid Airway Management Positioner in Obese Patients Undergoing Gastric Bypass or Laparoscopic Gastric Banding Surgery

Physiology Research

Is the Roux Limb a Determinant for Meal Size After Gastric Bypass Surgery?